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40.4±17.5 years with 76% males, respectively. Amongst the Hungarian patients 18% 
used none or only topical therapy in the last 12 months, 31% systemic non-bio-
logical treatment and 52% biologicals whereas in Iran 48% of the patients applied 
only topicals and 39% treated with non-biological systematic therapy. Mean EQ-5D, 
DLQI and PASI of the Hungarian and the Iranian sample were 0.69±0.3, 6.29±7.3, 
8.01±10, and 0.62±0.4, 10±6.5, 13±8.3, respectively. In both countries psoriasis of the 
neck and/or décolletage was associated with the greatest HRQOL reduction using 
either instrument (p< 0.05). Regarding clinical types, in Hungary the palmoplan-
tar involvement while in Iran nail psoriasis patients reported the worst general 
HRQOL (mean EQ-5D scores: 0.36±0.3 and 0.47±0.4). Correlation between EQ-5D 
and DLQI was found very similar across the two countries (rs= -0.43- and -0.44, 
p< 0.001), but EQ-5D showed significant correlation with PASI only in Hungary 
(rs= -0.43, p< 0.001). Strong positive correlation was identified between DLQI and 
PASI in both countries but only in those patients who received systemic therapy: 
Iran (rs= 0.72, p< 0.001) and Hungary (systemic non-biological: rs= 0.65, p< 0.001, 
biological: rs= 0.76, p< 0.001). ConClusions: Our results suggest that disease 
severity, treatments, and country-specific differences might lead to variations in 
the relationship between the outcome measures used in psoriasis.
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objeCtives: The Quality of Life in Hand Eczema Questionnaire (QOLHEQ) is a disease-
specific instrument to assess health-related Quality of Life (HRQOL) in hand eczema 
(HE) patients. The QOLHEQ assesses four domains of HRQOL: (a) symptoms, (b) emo-
tions, (c) functioning and (d) treatment/prevention. The QOLHEQ total-score ranges 
from 0-127 points. The aim of this study was to assign bands of the QOLHQ-score 
to an anchor question (AQ) on HE severity to aid the interpretation of the QOLHEQ-
score. Methods: Data was drawn from the German validation study of the QOLHEQ. 
We calculated median, mean and mode of the AQ for 30 categories of the QOLHEQ-
score to devise separate sets of bands. Weighted kappa was calculated in order to 
identify the set of bands with the best agreement between QOLHEQ and AQ. Results: 
Overall n= 316 HE patients were included in the study. Their mean age was 46.7 years 
(SD= 12.9) and 54.1% of the sample were female. With a weighted kappa of 0.54 the 
best agreement was found for the following band: QOLHEQ< 9 = minimal impairment; 
QOLHEQ 9-25 = slight impairment; QOLHEQ 25-58 = moderate impairment; QOLHEQ 
59-79 = severe impairment; QOLHEQ> 79 = very severe impairment. ConClusions: 
This is the first study which uses an anchor-based approach in order to devise a 
banding for the QOLHEQ-score. This banding represents a standardized means of 
interpreting the QOLHEQ total score. Further studies are needed to explore which 
banding may be adequate for different language version of the QOLHEQ.
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objeCtives: To identify conditioning factors of Health Related Quality of Life 
(HRQoL) of patients with psoriasis as reported in the literature in the last 5 years 
in Europe. Methods: Electronic databases [PubMed, ISI-WOK, Cochrane Library, 
MEDES, CSIC-IME, IBECS] and grey literature [Google Scholar], were searched to 
identify studies written in English or Spanish on HRQoL in patients with psoriasis, 
published in Europe between January 1, 2009 and December 31, 2013. Bibliographic 
references were hand searched. Editorials, letters, commentaries, opinion papers 
and studies related to specific treatments were excluded. Results: 27 stud-
ies accomplished the inclusion criteria. Most of the publications (66.7%, n= 18) 
were cross-sectional studies; 25.9% (n= 7) had a prospective design while 7.4% 
(n= 2) were retrospective. 12 studies analyzed the relation between HRQOL and 
demographic characteristics, determining in 75% and 50% of them, there was a 
relation between sex (women) and age (younger patients) with poorer HRQoL. 
3 publications demonstrated the HRQoL impairment associated with visibility of skin 
lesions. 4 studies appraised the relationship between disease activity and HRQoL 
determining a more compromised HRQOL in those patients with active psoriasis. 
Disease Severity was the most frequent assessed factor, being studied in 13 publica-
tions, describing in 92% of them that patients with higher PASI had worse HRQoL. 2 
articles indicated that disease symptoms as skin discomfort and pruritus were ele-
ments that negatively influenced the HRQoL of these patients. Emotional disturbances 
were identified as predictors of poorer HRQOL in 5 studies. 3 publications determined 
that the use of biologic therapy contributed to improve HRQoL. ConClusions: 
HRQoL has been broadly addressed in patients with psoriasis in Europe. Several 
disease- and patient-related factors contributed to its deterioration. Therapeutic 
measures with proved effectiveness in controlling disease symptoms and reducing 
PASI should be considered in patients with severe disease who have a relation with 
poorer HRQoL.
SenSory SyStemS diSorderS – Health Care use & Policy Studies
PSS52
CoSt-effeCtiveneSS and value of information analySeS of 
nutritional SuPPort in Preventing PreSSure ulCerS in HigH riSk 
HoSPitaliSed PatientS
Tuffaha H.W.1, Shelley R.2, Chaboyer W.2, Gordon L.G.1, Scuffham P.A.1
1Griffith University, Meadowbrook, Australia, 2Griffith University, Gold Coast, Australia
(Greece) to 42.8 (Germany) revealing an acceptable perception of HRQoL. Sleep, itch-
ing/embarrassment and mental health were the HRQoL dimensions most impaired. 
Patients taking prescription drugs were more satisfied than those taking over the 
counter (p< 0.01). Severely ill patients were willing to change therapies if new, more 
effective alternatives became available (p< 0.05). Only 1 study assessed the costs of 
CU in Europe while another one described the use of medical resources. CU total 
cost in France was € 2,139.48 per patient/year. Patients lost 2.2 working days/month, 
being productivity losses 92% of total costs. CU patients were mostly cared for a 
dermatologist according to findings in Germany. A mean of 11.7 (SD: 11.5) visits/
month to the dermatology clinic were reported. ConClusions: PROs and costs 
in CU are infrequently addressed in the literature. Findings show patients reduced 
HRQoL and their willingness for more effective therapies. Frequent medical visits 
and loss of productivity make CU a burdensome disease in European countries.
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objeCtives: Psoriasis is a chronic inflammatory skin condition that affects an 
estimated 4.5 to 7.5 million people in the United States. Numerous clinical trials 
have been conducted in psoriasis, many of which have included general derma-
tologic or psoriasis-specific PROs as study outcome measures. Commonly used 
PROs in these trials include the Dermatology Life Quality Index (DLQI), Psoriasis 
Disability Index (PDI), Psoriasis Life Stress Inventory (PLSI), Psoriasis Quality of Life 
Questionnaire (PQOL-12), and Skindex. This study assessed how well the develop-
ment and validation process of psoriasis-specific PROs align with the FDA PRO 
guidance. Methods: We reviewed the development and validation studies of the 
five PROs to assess if they align with the FDA PRO guidance criteria with regard to: 
(1) content validity, including patient input in concept elicitation, item generation, 
and cognitive debriefing; and (2) psychometric testing, including construct validity, 
internal-consistency and test-retest reliability, and responsiveness. Results: The 
PDI was developed without patient input in terms of concept elicitation, item gen-
eration, or cognitive debriefing. Variability and oftentimes inadequately documented 
evidence of patient input for concept elicitation, item generation, and cognitive 
debriefing were observed for the other four PROs. Test-retest reliability was not 
evaluated in the PLSI. Evidence of responsiveness was not available for three of the 
PROs. ConClusions: Based on this review, additional qualitative and quantitative 
research is needed to eliminate the identified gaps before these PROs could fulfill 
the FDA guidance for inclusion as a measure for a PRO label claim.
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objeCtives: The aim of this global survey was to evaluate the management of 
wet age-related macular degeneration (wAMD) from a patient/caregiver perspec-
tive. Methods: Patients with a wAMD diagnosis and current or prior use of intravit-
real injections and caregivers from nine countries (Australia, Brazil, Canada, France, 
Germany, Italy, Japan, Spain, and the UK) completed a questionnaire. Results: 910 
patients and 890 caregivers were surveyed. 55% of patients had wAMD in 1 eye and 
64% had been receiving intravitreal injections for > 1 year. Many caregivers were a 
child/grandchild of the patient (47%), or partner (23%); only 7% were a professional 
caregiver. Most (73%) patients visited a health care professional (HCP) within 1 
month of first noticing a change in vision; 41% of patients who delayed visiting 
a HCP thought the symptoms would resolve. Following diagnosis, 54% of patients 
began treatment immediately, and a further 37% scheduled an appointment within 
1–3 weeks. 52% of patients reported a temporary improvement or stabilization in 
vision as a result of current treatment, and 22% reported a return to pre-diagnosis 
vision or that their vision was still improving. Most patients and caregivers reported 
a number of obstacles in managing wAMD, including the treatment itself (35% and 
39%, respectively), treatment costs (28% and 29%), and finding the right treatment 
options (27% and 31%). Additionally, 27% of caregivers found the patient’s treat-
ment extremely inconvenient with 57% of employed (non-professional) caregivers 
having to take time off work or miss personal obligations. 16% of patients missed 
a HCP appointment because their caregiver was unable to take them (26%), fear of 
injections (21%), illness (19%), forgetfulness (15%), inconvenience (10%), costs (6%), 
and discomfort of injections (3%). ConClusions: Many patients and caregivers 
identified a number of obstacles in managing wAMD. These included the treatment 
itself (patients and caregivers) and loss of productivity (non-professional caregivers).
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objeCtives: To compare health-related quality of life (HRQOL) of Hungarian and 
Iranian psoriasis patients and to analyze possible differences in the relationship 
between EuroQol 5 dimensions (EQ-5D), Dermatology Life Quality Index (DLQI) 
and Psoriasis Area and Severity Index (PASI). Methods: Same cross-sectional 
questionnaire survey was carried out in two countries. Altogether 200 adult pso-
riasis patients enrolled from two Hungarian university clinics and 62 from an 
Iranian clinic. Besides HRQOL assessment, data on demographics, applied treat-
ments, affected body sites and clinical types were collected. Results: Mean age 
of the Hungarian and Iranian patients were 51.2 ±12.9 years with 69% males, and 
